UCL Institute of Health Informatics
London, NW1 2DA, United Kingdom
NCT Number: NCT06801925
This study aims to assess the feasibility and acceptability of a voice-based chatbot, powered by GPT-4o and Retrieval-Augmented Generation (RAG), for conducting depression screening using the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a validated self-report instrument widely used to screen, diagnose, and monitor the severity of depression. It consists of nine questions that correspond to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder. Respondents rate the frequency of symptoms experienced over the past two weeks on a scale from 0 ("not at all") to 3 ("nearly every day"). The total score (ranging from 0 to 27) indicates the severity of depressive symptoms, categorized into minimal, mild, moderate, moderately severe, or severe depression. The PHQ-9 is also used to assess functional impairment and guide treatment decisions in clinical and research settings.
The voice-based chatbot integrates GPT-4o, with RAG to enhance its ability to provide informed and contextualized responses during interactions. GPT-4o serves as the conversational engine, capable of generating human-like, empathetic, and contextually appropriate dialogue. RAG, on the other hand, enables the chatbot to retrieve and incorporate external, up-to-date knowledge from a curated database or knowledge repository, ensuring the accuracy and reliability of its responses.
Interested in participating?
Request Info18 year–65 year
All sexes
Observational
London, NW1 2DA, United Kingdom
Depression is a prevalent mental health challenge with significant personal, social, and economic costs. Traditional mental health resources face barriers such as stigma, limited availability, and long wait times. Technology, particularly AI-powered tools, provides an opportunity to bridge these gaps. This study utilizes GPT-4o and RAG to create a voice-interactive chatbot capable of conversational engagement, administering the PHQ-9 questionnaire, and delivering personalized feedback.
Participants will fill in the PHQ-9 for self-testing before interacting with the chatbot (the results will not be disclosed to the public and will only be used for accuracy comparisons), and the results of their self-tests will be compared with the results given by the chatbot in terms of accuracy.
The chatbot interaction comprises three phases:
Participants will interact with the chatbot and then participate in a 1-hour semi-structured interview to provide feedback on their experience. The study focuses on evaluating the acceptability and feasibility of using such LLM-based chatbots in mental health screening and identifying potential improvements and risks.
Study Objectives Primary Objectives
Hypothesis: Participants showed high acceptance of HopeBot (higher than 65%) and high willingness to use such LLM-based chatbot for mental health screening in the future (higher than 65%), indicating recognition of the credibility of LLM as a supportive tool in mental health screening (higher than 65%). Participants use of the HopeBot for depression screening matched their self-test PHQ-9 results by 100%
Hypothesis: HopeBot can help users take the PHQ-9 test in a friendly way, help users categorize the answers accurately, and give accurate test results, the advice they provide is based on the official PHQ-9 guidelines, and more than 70% of the users say that their responses are very effective and helpful.
Secondary Objectives
Hypothesis: Over 65% of participants recognized that responses using RAG were more helpful and effective.
Hypothesis: More than 65% of users say that HopeBot is very convenient, more accessible, and cost-free to provide non-judgmental advice. However, 50% still expressed concerns about its privacy and data security.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This study involves the use of a voice-based chatbot powered by GPT-4o and Retrieval-Augmented Generation (RAG) to conduct depression screening using the Patient Health Questionnaire-9 (PHQ-9).
The chatbot aims to evaluate the feasibility and acceptability of using AI-powered conversational tools for mental health screening.
Participants interact with the chatbot in a single session, answering PHQ-9 questions and receiving responses generated using GPT-4o and RAG technologies.
Time frame: Interviews are conducted immediately following the chatbot interaction.
Participants' perceptions of the chatbot's feasibility, acceptability, and effectiveness are assessed through semi-structured interviews conducted after the interaction session. These interviews explore themes such as the chatbot's empathy, usability, and the overall user experience.
Time frame: Measured immediately after the interaction session, once the chatbot has generated PHQ-9 scores
The accuracy of the PHQ-9 scores generated by the chatbot is measured by comparing the chatbot's results to participants' self-reported PHQ-9 scores collected prior to the interaction. Agreement will be assessed using statistical methods such as Cohen's kappa or intraclass correlation coefficient (ICC).
University College, London
Other
Acronym: GPT4-RAG-PHQ
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07064928
Acquired Immunodeficiency Syndrome, Behavior
Accra, Ghana
View Trial DetailsNCT07617467
Anxiety, Anxiety Depression
Arendal, Agder, Norway
View Trial DetailsNCT06981000
Anxiety, Anxiety Disorders
Copenhagen, Denmark
View Trial DetailsNCT07390786
Anxiety, Anxiety Disorders
Charleston, South Carolina, United States
View Trial Details